Sterling Capital Management
SPRB icon

Sterling Capital Management’s Spruce Biosciences SPRB Stock Holding History

Sterling Capital Management’s Portfolio SPRB Stock Details SPRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$2.87K Buy
59
+16
+37% +$811 ﹤0.01% 3074
2026
Q2 		$2.32K Buy
+43
New +$2.4K ﹤0.01% 2955

Other funds holding SPRB

ACM
AIGH Capital Management Baltimore, Maryland $992M AUM 516.32% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Carlyle Group
Carlyle Group Washington, District of Columbia $8.36B AUM 14.46% 1-Year Est. Return
Quinn Opportunity Partners
Quinn Opportunity Partners Charlottesville, Virginia $1.85B AUM 1.27% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
RhumbLine Advisers
RhumbLine Advisers Boston, Massachusetts $134B AUM 35.21% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $420B AUM 34.97% 1-Year Est. Return

Sterling Capital Management's SPRB Position: Q3 2026 in Review

Sterling Capital Management increased its Spruce Biosciences (SPRB) stake by 37% in Q3 2026, buying an estimated $811 and bringing the position to 59 shares worth $2.87K. The position accounts for ﹤0.01% of the portfolio, ranked #3074.

Sterling Capital Management first reported a position in SPRB in Q2 2026 and has held it in 2 quarters since. 26 funds tracked by Wall St. Rank hold SPRB as of Q3 2026.

  • Sterling Capital Management held 59 shares of Spruce Biosciences worth $2.87K as of Q3 2026.
  • Sterling Capital Management bought 16 Spruce Biosciences shares in Q3 2026, an estimated $811.
  • Spruce Biosciences made up ﹤0.01% of Sterling Capital Management's portfolio in Q3 2026, its #3074 holding.
  • Sterling Capital Management first reported a position in Spruce Biosciences in Q2 2026 and has held it in 2 quarters since.
  • 26 funds tracked by Wall St. Rank held Spruce Biosciences as of Q3 2026.

Based on Sterling Capital Management's 13F filing for Q3 2026, filed 22 Oct 2026.